Top

Published in:

01-08-2009 | Original Article

Silencing CD147 inhibits tumor progression and increases chemosensitivity in murine lymphoid neoplasm P388D1 cells

Authors: Li Jia, Wei Wei, Jun Cao, Henggui Xu, Xiaoyan Miao, Jianing Zhang

Published in: Annals of Hematology | Issue 8/2009

Abstract

Overexpression of extracellular matrix metalloproteinase inducer (EMMPRIN or CD147), a member glycoprotein enriched on the surface of many malignant tumor cells, promotes tumor progression and confers resistance to some chemotherapeutic drugs. To investigate the possible role of CD147 in the macrophage-like lymphoid neoplasm P388D1 cells progression, we used RNA interference approach to silence CD147 expression. The results showed that silencing of CD147 in P388D1 cells impeded the expression of MMP11 at both mRNA and protein levels. The reduced CD147 expression also resulted in reductions in tumorigenicity, as well as decreased in regional lymph node metastasis. Furthermore, the down-regulation of CD147 expression sensitized cells to be more sensitive to chemotherapeutic drugs. Treatment of tumor cells with U-0126, an inhibitor of mitogen-activated protein kinase/Erk, also down-regulated the expression of MMP11. Our current results indicate that the expression of CD147 functionally mediates tumor progression and is a potential target for therapeutic anti-cancer drugs.

Gabison EE, Hymowitz M, Rollo EE, Mann R, Conner CE, Cao J et al (2005) EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie 87:361–368 doi:10.1016/j.biochi.2004.09.023 PubMedCrossRef

Zucker S, Hymowitz M, Rollo EE, Mann R, Conner CE, Cao J et al (2001) Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol 158:1921–1928PubMed

Reimers N, Zafrakas K, Assmann V, Egen C, Riethdorf L, Riethdorf S et al (2004) Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 10:3422–3428 doi:10.1158/1078-0432.CCR-03-0610 PubMedCrossRef

Davidson B, Konstantinovsky S, Nielsen S, Dong HP, Berner A, Vyberg M et al (2004) Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. Clin Cancer Res 10:7335–7346 doi:10.1158/1078-0432.CCR-04-0183 PubMedCrossRef

Misra S, Ghatak S, Zoltan-Jones A, Toole BP (2003) Regulation of multidrug resistance in cancer cells by hyaluronan. J Biol Chem 278:25285–25288 doi:10.1074/jbc.C300173200 PubMedCrossRef

Zou W, Zhu H, Wu X (2006) Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to paclitaxel in HO-8910pm cells. Cancer Lett 248:211–218 doi:10.1016/j.canlet.2006.07.005 PubMedCrossRef

Caudroy S, Polette M, Nawrocki-Raby B, Cao J, Toole BP, Zucker S et al (2002) EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis 19:697–702 doi:10.1023/A:1021350718226 PubMedCrossRef

Li R, Huang L, Guo H, Toole BP (2001) Basigin (murine EMMPRIN) stimulates matrix metalloproteinase production by fibroblasts. J Cell Physiol 186:371–379 doi:10.1002/1097-4652(2000)9999:999<000::AID-JCP1042>3.0.CO;2-8 PubMedCrossRef

Sun J, Hemler ME (2001) Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 61:2276–2281PubMed

10.

Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135–1149PubMed

11.

Illemann M, Bird N, Majeed A, Sehested M, Laerum OD, Lund LR et al (2005) MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res 4:293–302 doi:10.1158/1541-7786.MCR-06-0003 CrossRef

12.

Davidson B, Givant-Horwitz V, Laranovici P, Risberg B, Nesland JM, Trope CG et al (2002) Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma. Clin Exp Metastasis 20:621–631 doi:10.1023/A:1027347932543 CrossRef

13.

Lim M, Martinez T, Jablons D, Cameron R, Guo H, Toole B et al (1998) Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38. FEBS Lett 441:88–92 doi:10.1016/S0014-5793(98)01474-4 PubMedCrossRef

14.

Khunkeawla P, Moonsom S, Staffler G, Kongtawelert P, Kasinrer KW (2001) Engagement of CD147 molecule-induced cell aggregation through the activation of protein kinases and reorganization of the cytoskeleton. Immunobiology 203:659–669PubMed

15.

Jia L, Wang S, Cao J, Zhou H, Wei W, Zhang J (2007) siRNA targeted against matrix metalloproteinase 11 inhibits the metastatic capability of murine Hepatocarcinoma cell Hca-F to lymph nodes. IJBCB 39:2049–2062

16.

Kanekura T, Chen X, Kanzaki T (2002) Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 99:520–528 doi:10.1002/ijc.10390 PubMedCrossRef

17.

Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P et al (2005) Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 65:3193–3199PubMed

18.

Delebecq TJ, Porte H, Zerimech F, Copin MC, Gouyer V, Dacquembronne E et al (2000) Overexpression level of stromelysin 3 is related to the lymph node involvement in nonsmall cell lung cancer. Clin Cancer Res 6:1086–1092PubMed

19.

Deng H, Guo RF, Li WM, Zhao M, Lu YY (2005) Matrix metalloproteinase 11 depletion inhibits cell proliferation in gastric cancer cells. BBRC 14:274–281

20.

Jia L, Cao J, Wei W, Wang S, Zuo Y, Zhang J (2007) CD147 depletion down-regulates matrix metalloproteinase-11, vascular endothelial growth factor-A expression and the lymphatic metastasis potential of murine Hepatocarcinoma Hca-F. IJBCB 39:2135–2142

21.

Klein CA, Seidl S, Petat-Dutter K, Offner S, Geigl JB, Schmidt-Kittler O et al (2002) Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol 20:387–392 doi:10.1038/nbt0402-387 PubMedCrossRef

22.

Li QQ, Wang WJ, Xu JD, Cao XX, Chen Q, Yang JM et al (2007) Involvement of CD147 in regulation of multidrug resistance to P-gp substrate drugs and in vitro invasion in breast cancer cells. Cancer Sci 98:1064–1069 doi:10.1111/j.1349-7006.2007.00487.x PubMedCrossRef

23.

Yang JM, Xu Z, Wu H, Zhu H, Wu X, Hait WN (2003) Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res 1:420–427PubMed

24.

Yang JM, Vassil AD, Hait WN (2001) Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway. Mol Pharmacol 60:674–680PubMed

25.

Huang C, Jacobson K, Schaller MD (2004) MAP kinases and cell mobility. J Cell Sci 117:4619–4628 doi:10.1242/jcs.01481 PubMedCrossRef

26.

Brauchle M, Gluck D, Padova FD, Han JH, Gram H (2000) Independent role of p38 and ERK1/2 mitogen-activated kinases in the upregulation of matrix metalloproteinase-1. Exp Cell Res 258:135–144 doi:10.1006/excr.2000.4913 PubMedCrossRef

Title: Silencing CD147 inhibits tumor progression and increases chemosensitivity in murine lymphoid neoplasm P388D1 cells
Authors: Li Jia
Wei Wei
Jun Cao
Henggui Xu
Xiaoyan Miao
Jianing Zhang
Publication date: 01-08-2009
Publisher: Springer-Verlag
Published in: Annals of Hematology / Issue 8/2009
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-008-0678-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2009

Hemin-induced suicidal erythrocyte death

Early onset of acute lymphoblastic leukemia with MLL rearrangement after autologous stem cell transplantation for multiple myeloma

A rare combination of two inherited disorders in one patient: pyruvate kinase deficiency and hemochromatosis

Association of sickle avascular necrosis with bone morphogenic protein 6

Hemoperitoneum due to spontaneous rupture of the left gastroepiploic artery in a patient with hemophilia A

A complex 1;19;11 translocation involving the MLL gene in a patient with congenital acute monoblastic leukemia identified by molecular and cytogenetic techniques

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials